Journal of Clinical Oncology (JCO) Podcast

Latest Episodes:

How Should We Manage the Financial Toxicity of Cancer Treatment? Mar 09, 2016

Show notes

A study by Ramsey and colleagues suggests that extreme financial distress as manifested by personal bankruptcy might be associated with worse mortality in cancer patients. Long-term solutions have to focus on policy shifts involving how we set prices for drugs and how we design health insurance, but for more immediate solutions interventions have to focus on the oncologist and patient.

Prognostication in Mantle Cell Lymphoma Feb 29, 2016

Show notes

The Ki-67 proliferation index improves the prognostic value of the MIPI score.

Sunbelt Melanoma Trial: A Seminal Adjuvant Interferon Trial with Long Term Results Feb 08, 2016

Show notes

Race for the Cure: How differences in Race and Ethnicity Impact the Diagnosis and Survival of T-Cell Lymphoma Jan 25, 2016

Show notes

Ethnicity’s impact on diagnosis and survival of T-cell lymphoma

Clinical Drug Development for Non-Muscle-Invasive Bladder Cancer…Definitions Matter Jan 25, 2016

Show notes

This podcast reviews the International Bladder Cancer Group’s recommendations regarding definitions and endpoints for the development of non-muscle-invasive bladder cancer clinical trials.

Hepatocellular Carcinoma in Children and Adolescents: Time for a Strategy and a Trial Jan 25, 2016

Show notes

An update on clinical trials that have included children with hepatocellular carcinoma

Epidural Spinal Cord Compression: The Importance of Multi-disciplinary Treatment Planning Jan 12, 2016

Show notes

Hard to RECIST: Updating and Simplifying Primary Tumor Response Guidelines for the Revised International Neuroblastoma Response Criteria (INRC) Jan 11, 2016

Show notes

This podcast reviews the accompanying article to provide the audience an understanding of the data and rationale to support updating the INRC primary site response criteria.

Expanding Immunotheapy Benefit in Metastatic RCC Jan 11, 2016

Show notes

Discussion of a phase I trial of the checkpoint inhibitor atezolizumab in metastatic renal carcinoma.

A New Oncogene Target in Lung Cancer: Exon 14 Alterations in the MET Gene Jan 04, 2016

Show notes